Jafron Biomedical Co Ltd (300529) — Net Asset Quality Index
Jafron Biomedical Co Ltd (300529) has a Net Asset Quality Index of 66.6% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.20 Billion minus total liabilities of CN¥1.74 Billion yields net assets of CN¥3.46 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read Jafron Biomedical Co Ltd (300529) total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Jafron Biomedical Co Ltd Net Asset Quality Index Over Time (2011–2025)
This chart shows how Jafron Biomedical Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 66.6%, representing net assets of CN¥3.46 Billion against total assets of CN¥5.20 Billion CNY. For live market cap and overall valuation, see 300529 stock market capitalisation.
Annual Net Asset Quality Index for Jafron Biomedical Co Ltd (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Jafron Biomedical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check strategic asset allocation of Jafron Biomedical Co Ltd to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 64.2% | CN¥3.47 Billion | CN¥5.41 Billion | CN¥1.94 Billion | ▲ +2.2 pp |
| 2024 | 61.9% | CN¥3.33 Billion | CN¥5.38 Billion | CN¥2.05 Billion | ▲ +5.1 pp |
| 2023 | 56.9% | CN¥3.15 Billion | CN¥5.54 Billion | CN¥2.39 Billion | ▼ -9.4 pp |
| 2022 | 66.3% | CN¥3.59 Billion | CN¥5.41 Billion | CN¥1.82 Billion | ▼ -4.0 pp |
| 2021 | 70.3% | CN¥3.38 Billion | CN¥4.81 Billion | CN¥1.43 Billion | ▼ -17.7 pp |
| 2020 | 88.1% | CN¥2.83 Billion | CN¥3.22 Billion | CN¥383.06 Million | ▲ +1.1 pp |
| 2019 | 87.0% | CN¥2.17 Billion | CN¥2.49 Billion | CN¥324.13 Million | ▲ +3.1 pp |
| 2018 | 83.9% | CN¥1.72 Billion | CN¥2.05 Billion | CN¥330.04 Million | ▲ +2.2 pp |
| 2017 | 81.7% | CN¥1.39 Billion | CN¥1.70 Billion | CN¥310.90 Million | ▼ -9.4 pp |
| 2016 | 91.1% | CN¥1.18 Billion | CN¥1.30 Billion | CN¥115.81 Million | ▲ +9.2 pp |
| 2015 | 81.9% | CN¥564.06 Million | CN¥688.67 Million | CN¥124.61 Million | ▼ -2.0 pp |
| 2014 | 83.9% | CN¥452.42 Million | CN¥539.01 Million | CN¥86.59 Million | ▲ +1.6 pp |
| 2013 | 82.3% | CN¥380.12 Million | CN¥461.73 Million | CN¥81.60 Million | ▼ -2.8 pp |
| 2012 | 85.1% | CN¥290.84 Million | CN¥341.58 Million | CN¥50.74 Million | ▼ -2.4 pp |
| 2011 | 87.5% | CN¥215.57 Million | CN¥246.24 Million | CN¥30.68 Million | — |